ARL6IP5 and breast carcinoma: Previous studies have shown that ARL6IP5 downregulation caused increased cell migration and invasion in malignant melanoma, osteosarcoma, cervical carcinoma, esophageal carcinoma, and breast carcinoma [36, 39, 45].